 |
 |
-- [ From: Donna Kipp * EMC.Ver #2.10P ] -- Sessio DR: Pearlstone MM, Jewelewicz R; Kelly A C Estrogens and Parkinson's disease Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, New York, New York 10032 Med Hypotheses 1994 Apr,42(4):280-2 Unique Identifier: SDILINE 94352251 There is substantial evidence that estrogens modulate the activity of dopamine in the extrapyramidal system. However there is conflicting data as to the exact mechanism of estrogen's effect. The majority of clinicians reports support an antidopaminergic effect of estrogens on Parkinson's symptoms. Generally, Parkinsonism worsens with estrogen therapy. We report a case of improvement in Parkinsonian symptoms in a premenopausal patient when put in leuprolide acetate. The pharmacologic menopause induced by leuprolide acetate leads to a hypoestrogenic state. We hypothesize that the decrease in estrogen improves Parkinson's disease symptoms via relief of its antidopaminergic effects on the nigrostriatal pathway. The address for the newsletter is: The Young Parkinson's Information and Referral Center 1042 Foxenwoods Dr, Santa Maria CA 93455